Rockwell Medical (RMTI) 10-Q15 Aug 222022 Q2 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2022	Aug. 12, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	000-23661
Entity Registrant Name	ROCKWELL MEDICAL, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	38-3317208
Entity Address, Address Line One	30142 S. Wixom Road
Entity Address, City or Town	Wixom
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48393
City Area Code	248
Local Phone Number	960-9009
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	RMTI
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding (in shares)		10,675,193
Entity Central Index Key	0001041024
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
ASSETS
Cash and Cash Equivalents	$ 30,780	$ 13,280
Investments Available-for-Sale	0	9,158
Accounts Receivable, net	8,090	5,913
Inventory, net	5,171	4,076
Prepaid and Other Current Assets	3,204	2,861
Total Current Assets	47,245	35,288
Property and Equipment, net	2,289	2,486
Inventory, Non-Current	1,481	1,523
Right of Use Assets, net	6,671	7,737
Goodwill	921	921
Other Non-Current Assets	509	619
Total Assets	59,116	48,574
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts Payable	2,942	3,739
Accrued Liabilities	4,660	5,090
Lease Liability - Current	1,935	2,004
Deferred License Revenue - Current	2,169	2,171
Term Loan - Net of Issuance Costs	5,131	7,381
Insurance Financing Note Payable	1,509	437
Customer Deposits	189	144
Total Current Liabilities	18,535	20,966
Lease Liability - Long-Term	4,947	5,887
Term Loan, Net of Issuance Costs	10,370	13,186
Deferred License Revenue - Long-Term	5,105	5,986
Long Term Liability - Other	14	14
Total Liabilities	38,971	46,039
Stockholders’ Equity:
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; 15,000 and nil shares issued and outstanding at June 30, 2022 and December 31, 2021	0	0
Common Stock, $0.0001 par value; 170,000,000 shares authorized; 9,407,296 and 8,544,225 shares issued and outstanding at June 30, 2022 and December 31, 2021	1	1
Additional Paid-in Capital	402,304	372,562
Accumulated Deficit	(382,209)	(370,080)
Accumulated Other Comprehensive Income	49	52
Total Stockholders’ Equity	20,145	2,535
Total Liabilities and Stockholders’ Equity	$ 59,116	$ 48,574
Preferred shares, shares outstanding (in shares)	15,000	0
Preferred shares, shares issued (in shares)	15,000	0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred shares, shares authorized (in shares)	2,000,000	2,000,000
Preferred shares, shares issued (in shares)	15,000	0
Preferred shares, shares outstanding (in shares)	15,000	0
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common shares, shares authorized (in shares)	170,000,000	170,000,000
Common shares, shares issued (in shares)	9,407,296	8,544,225
Common shares, shares outstanding (in shares)	9,407,296	8,544,225

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Net Sales	$ 18,682	$ 15,137	$ 34,806	$ 30,611
Cost of Sales	16,937	15,399	33,846	30,471
Gross (Loss) Profit	1,745	(262)	960	140
Research and Product Development	926	2,416	2,494	4,224
Selling and Marketing	526	1,468	981	3,319
General and Administrative	4,775	3,677	8,592	7,602
Operating Loss	(4,482)	(7,823)	(11,107)	(15,005)
Other (Expense) Income
Realized Gain on Investments	0	(1)	4	(1)
Interest Expense	(485)	(583)	(1,021)	(1,164)
Interest Income	0	7	(4)	18
Total Other Expense	(485)	(577)	(1,021)	(1,147)
Net Loss	$ (4,967)	$ (8,400)	$ (12,128)	$ (16,152)
Basic Net Loss per Share (in dollars per share)	$ (0.56)	$ (0.99)	$ (1.40)	$ (1.90)
Diluted Net Loss per Share (in dollars per share)	$ (0.56)	$ (0.99)	$ (1.40)	$ (1.90)
Basic Weighted Average Shares Outstanding (in shares)	8,805,190	8,518,499	8,675,428	8,513,417
Diluted Weighted Average Shares Outstanding (in shares)	8,805,190	8,518,499	8,675,428	8,513,417

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net Loss	$ (4,967)	$ (8,400)	$ (12,128)	$ (16,152)
Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments	0	(1)	0	(8)
Foreign Currency Translation Adjustments	(2)	0	(3)	3
Comprehensive Loss	$ (4,969)	$ (8,401)	$ (12,131)	$ (16,157)

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Public Offering	At-the-Market Offering	PREFERRED STOCK	COMMON STOCK	COMMON STOCK Public Offering	COMMON STOCK At-the-Market Offering	ADDITIONAL PAID-IN CAPITAL	ADDITIONAL PAID-IN CAPITAL Public Offering	ADDITIONAL PAID-IN CAPITAL At-the-Market Offering	ACCUMULATED DEFICIT	ACCUMULATED OTHER COMPREHENSIVE INCOME
Beginning balance (in shares) at Dec. 31, 2020					8,506,651
Beginning balance at Dec. 31, 2020	$ 34,170				$ 1			$ 371,518			$ (337,406)	$ 57
Increase (Decrease) in Shareholders' Equity
Net Loss	(7,752)										(7,752)
Unrealized Loss on Available-for-Sale Investments	(7)											(7)
Foreign Currency Translation Adjustments	3											3
Stock-based Compensation expense (in shares)					2,396
Stock-based Compensation and modification expense	(236)							(236)
Ending balance (in shares) at Mar. 31, 2021					8,509,047
Ending balance at Mar. 31, 2021	26,178				$ 1			371,282			(345,158)	53
Beginning balance (in shares) at Dec. 31, 2020					8,506,651
Beginning balance at Dec. 31, 2020	34,170				$ 1			371,518			(337,406)	57
Increase (Decrease) in Shareholders' Equity
Net Loss	(16,152)
Unrealized Loss on Available-for-Sale Investments	(8)
Foreign Currency Translation Adjustments	3
Ending balance (in shares) at Jun. 30, 2021					8,528,307
Ending balance at Jun. 30, 2021	18,203				$ 1			371,708			(353,558)	52
Beginning balance (in shares) at Mar. 31, 2021					8,509,047
Beginning balance at Mar. 31, 2021	26,178				$ 1			371,282			(345,158)	53
Increase (Decrease) in Shareholders' Equity
Net Loss	(8,400)										(8,400)
Unrealized Loss on Available-for-Sale Investments	(1)											(1)
Foreign Currency Translation Adjustments	0
Stock-based Compensation and modification expense	433							433
Vesting of Restricted Stock Units Issued, net of taxes withheld (in shares)					19,260
Vesting of Restricted Stock Units Issued, net of taxes withheld	(7)							(7)
Ending balance (in shares) at Jun. 30, 2021					8,528,307
Ending balance at Jun. 30, 2021	$ 18,203				$ 1			371,708			(353,558)	52
Beginning balance (in shares) at Dec. 31, 2021	0			0
Beginning balance (in shares) at Dec. 31, 2021	8,544,225				8,544,225
Beginning balance at Dec. 31, 2021	$ 2,535				$ 1			372,562			(370,080)	52
Increase (Decrease) in Shareholders' Equity
Net Loss	(7,162)										(7,162)
Foreign Currency Translation Adjustments	(1)											(1)
Stock-based Compensation and modification expense	(179)							(179)
Ending balance (in shares) at Mar. 31, 2022				0
Ending balance (in shares) at Mar. 31, 2022					8,544,225
Ending balance at Mar. 31, 2022	$ (4,807)				$ 1			372,383			(377,242)	51
Beginning balance (in shares) at Dec. 31, 2021	0			0
Beginning balance (in shares) at Dec. 31, 2021	8,544,225				8,544,225
Beginning balance at Dec. 31, 2021	$ 2,535				$ 1			372,562			(370,080)	52
Increase (Decrease) in Shareholders' Equity
Net Loss	(12,128)
Unrealized Loss on Available-for-Sale Investments	0
Foreign Currency Translation Adjustments	$ (3)
Ending balance (in shares) at Jun. 30, 2022	15,000			15,000
Ending balance (in shares) at Jun. 30, 2022	9,407,296				9,407,296
Ending balance at Jun. 30, 2022	$ 20,145				$ 1			402,304			(382,209)	49
Beginning balance (in shares) at Mar. 31, 2022				0
Beginning balance (in shares) at Mar. 31, 2022					8,544,225
Beginning balance at Mar. 31, 2022	(4,807)				$ 1			372,383			(377,242)	51
Increase (Decrease) in Shareholders' Equity
Net Loss	(4,967)										(4,967)
Unrealized Loss on Available-for-Sale Investments	0
Foreign Currency Translation Adjustments	(2)											(2)
Issuance of stock, net of offering costs (in shares)				15,000		844,613	7,500
Issuance of stock, net of offering costs (in dollars)	14,916	$ 14,893	$ 15					14,916	$ 14,893	$ 15
Stock-based Compensation and modification expense	$ 97							97
Vesting of Restricted Stock Units Issued, net of taxes withheld (in shares)					10,958
Ending balance (in shares) at Jun. 30, 2022	15,000			15,000
Ending balance (in shares) at Jun. 30, 2022	9,407,296				9,407,296
Ending balance at Jun. 30, 2022	$ 20,145				$ 1			$ 402,304			$ (382,209)	$ 49

UNAUDITED CONDENSED CONSOLIDA_4

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash Flows From Operating Activities:
Net Loss	$ (12,128)	$ (16,152)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization	279	385
Stock-based Compensation	(82)	197
Increase in Inventory Reserves	10	89
Amortization of Right of Use Asset	1,027	857
Amortization of Debt Financing Costs and Accretion of Debt Discount	184	184
(Gain) Loss on Disposal of Assets	(2)	8
Realized (Gain) Loss on Sale of Investments Available-for-Sale	(4)	1
Foreign Currency Translation Adjustment	(3)	3
Changes in Assets and Liabilities:
Increase in Accounts Receivable, net	(2,177)	(1,186)
Increase in Inventory	(1,063)	(799)
Decrease in Prepaid and Other Assets	1,275	1,293
(Decrease) Increase in Accounts Payable	(797)	777
Decrease in Lease Liability	(969)	(839)
Decrease in Other Liabilities	(385)	(1,163)
Decrease in Deferred License Revenue	(883)	(1,088)
Changes in Assets and Liabilities	(4,999)	(3,005)
Cash Used In Operating Activities	(15,718)	(17,433)
Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale	(2,810)	(13,765)
Sale of Investments Available-for-Sale	11,972	15,181
Purchase of Equipment	(80)	(281)
Cash Provided By Investing Activities	9,082	1,135
Cash Flows From Financing Activities:
Payments on Debt	(5,250)	0
Payments on Short Term Note Payable	(439)	0
Proceeds from the Issuance of Common Stock	15,016	0
Offering Costs from the Issuance of Common Stock	106	0
Proceeds from the Issuance of Preferred Shares	15,000	0
Offering Costs from the Issuance of Preferred Stock	(85)	0
Repurchase of Common Stock to Pay Employee Withholding Taxes	0	(6)
Cash Provided by (Used In) Financing Activities	24,136	(6)
Increase (Decrease) in Cash and Cash Equivalents	17,500	(16,304)
Cash and Cash Equivalents at Beginning of Period	13,280	48,682
Cash and Cash Equivalents at End of Period	30,780	32,378
Supplemental Disclosure of Cash Flow Information:
Cash Paid for Interest	998	982
Supplemental Disclosure of Noncash Investing and Financing Activities:
Change in Unrealized Loss on Marketable Securities Available-for-Sale	$ 0	$ (7)

Description of Business

Description of Business	6 Months Ended
Description of Business	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Rockwell Medical, Inc. ("Rockwell Medical," "Rockwell," or the "Company") is a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney. Rockwell is a revenue-generating business and the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage renal disease treatment and is usually performed at a freestanding outpatient dialysis center, at a hospital-based outpatient center, or at the patient’s home. We manufacture our hemodialysis concentrates under cGMP regulations at our three facilities in Michigan, Texas, and South Carolina totaling approximately 175,000 square feet, from which we deliver these products to dialysis clinics throughout the United States with our own delivery fleet as well as third parties. We also manufacture mixers that are used by clinics in our Iowa facility. Rockwell has developed a core expertise in manufacturing and delivering hemodialysis concentrates, and has built a longstanding reputation for reliability, quality, and excellent customer service. Rockwell commercializes Triferic in the United States, an FDA-approved treatment indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. Rockwell also has a number of partnerships with companies seeking to develop and commercialize Triferic outside the United States. Rockwell is working closely with these partners to progress these programs. We have an emerging portfolio of drug development candidates we are pursuing. Rockwell is developing a next-generation, proprietary parenteral iron technology platform, Ferric Pyrophosphate Citrate (“FPC”). We believe our FPC platform has several advantages over other parenteral iron therapies by immediately providing bioavailable iron for critical body processes once it is administered. Rockwell is moving product candidates derived from this platform into the clinic to treat iron-deficiency anemia in the home infusion setting and for acute heart failure. Together, with our dedicated employees and deep expertise in manufacturing and logistics and pharmaceutical development and commercialization. Rockwell is well-positioned to realize sustainable business growth and support our mission to provide life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney.

Liquidity and Capital Resources

Liquidity and Capital Resources	6 Months Ended
Liquidity and Capital Resources	Jun. 30, 2022
Liquidity and Going Concern Considerations [Abstract]
Liquidity and Capital Resources	Liquidity and Capital Resources As of June 30, 2022, Rockwell had approximately $30.8 million of cash and cash equivalents and working capital of $28.7 million. Net cash used in operating activities for the six months ended June 30, 2022 was approximately $15.7 million. Based on the currently available working capital and capital raises described below, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report. On April 6, 2022, the Company and DaVita, Inc. ("DaVita") entered into an amendment (the "Amendment") to the Products Purchase Agreement, dated July 1, 2019, under which the Company supplies DaVita with certain dialysis concentrates. Under the Amendment, the Company and DaVita agreed to certain price increases, effective May 1, 2022, as well as the pass-through of certain inflationary costs, determined on a quarterly basis. Certain costs are subject to a cap. The Amendment also requires the Company to implement certain cost containment and cost-cutting measures. The Amendment contains certain covenants with respect to the Company’s ongoing operations, including a minimum cash covenant of $10 million, or we will be in default under the Products Purchase Agreement. An event of default could result in termination of that agreement. On April 6, 2022, the Company and DaVita entered into a Securities Purchase Agreement (the “SPA”), pursuant to which the Company issued $15 million of preferred stock to DaVita in two separate tranches. The Company initially issued 7,500 shares of a newly designated series of preferred stock, which is designated “Series X Convertible Preferred Stock” (the “Series X Preferred Stock”) for gross proceeds of $7.5 million. On June 15, 2022, the Company issued to DaVita an additional 7,500 shares of Series X Preferred Stock in a second closing (the “Second Tranche”) for an additional $7.5 million. The Second Tranche was conditioned upon the Company raising an additional $15 million in capital within a certain timeline, which took place on June 2, 2022. On April 8, 2022, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the Securities and Exchange Commission (“SEC”) on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022. As of June 30, 2022, the Company sold 7,500 shares of its common stock pursuant to the Sales Agreement for gross proceeds of $15,135, at a weighted average selling price of approximately $2.02 The Company paid $378 in commissions and offering fees. Approximately $12.2 million remains available for sale under the ATM facility. On May 30, 2022, the Company entered into a Securities Purchase Agreement (the “RD Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and prefunded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share. Also on May 30, 2022, concurrently with the Offering, the Company entered into a Securities Purchase Agreement with the Purchaser (the “PIPE Purchase Agreement”) relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share. The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses. The Company expects it will require additional capital to sustain its operations and make the investments it needs to execute its strategic plan in developing FPC for iron deficiency anemia in patients undergoing home infusion and for progressing our pipeline development program of new indications for our FPC platform. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume such financing will be available on favorable terms, if at all. Currently, because the Company's public float is less than $75 million, we are subject to the baby shelf limitations under our current registration statement on Form S-3, which limit the amount we may offer under our Form S-3. This could limit our ability to raise capital under this registration statement. As previously reported, on June 11, 2021, the Company received written notice (the "Notification Letter") from the Nasdaq Stock Market ("Nasdaq") notifying the Company it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities maintain a minimum closing bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common stock for the 30 consecutive business days prior to the date of the Notification Letter, the Company did not meet the minimum closing bid price requirement. The Notification Letter provided for 180 calendar days, or until December 8, 2021, for the Company to regain compliance with Nasdaq Listing Rule 5450(a)(1). To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to December 8, 2021. The Company was not able to meet the minimum compliance requirements set forth by Nasdaq by December 8, 2021. On December 9, 2021, the Company received a written notice from Nasdaq indicating the Company’s application to transfer its listing venue from The Nasdaq Global Market to The Nasdaq Capital Market for its common stock had been approved. The Company’s common stock commenced trading on The Nasdaq Capital Market at the opening of business on December 10, 2021 under the symbol “RMTI.” Also on December 9, 2021, the Company received written notice that Nasdaq has determined the Company was eligible for an additional 180-day extension, or until June 6, 2022, to regain compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to June 6, 2022. On May 13, 2022, the Company effected a reverse stock split and on May 31, 2022 Nasdaq notified the Company it had regained compliance with the minimum bid price requirement (see Note 3 for further detail). In addition, the Company is subject to certain covenants and cure provisions under its Loan Agreement with Innovatus. As of the date of this report, the Company is in compliance with all covenants (See Note 14 for further detail). The COVID-19 pandemic and resulting domestic and global disruptions, particularly in the supply chain and labor market, among other areas, have adversely affected our business and operations, including, but not limited to, our sales and marketing efforts and our research and development activities, our plant and transportation operations and the operations of third parties upon whom we rely. The Company's international business development activities may also continue to be negatively impacted by COVID-19. The COVID-19 pandemic and the resulting global disruptions and recent inflationary pressures have caused significant volatility in financial and credit markets. Rockwell has utilized a range of financing methods to fund its operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements	Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet at June 30, 2022, condensed consolidated statements of operations for the three and six months ended June 30, 2022 and 2021, condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2022 and 2021, condensed consolidated statement of changes in stockholders' equity for the three and six months ended June 30, 2022 and 2021, and condensed consolidated statements of cash flows for the six months ended June 30, 2022 and 2021 are unaudited, but include all adjustments, consisting of normal recurring adjustments, the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and six months ended June 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022 or for any future interim period. The condensed consolidated balance sheet at December 31, 2021 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the SEC on April 8, 2022. The Company’s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. Reverse Stock Split On May 9, 2022, the stockholders of the Company authorized our Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series X convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to account for the effect of the reverse stock split for the three and six month periods ended June 30, 2022 and 2021, respectively, and the balance sheet at June 30, 2022 and December 31, 2021. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Leases The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases . Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term. Loss Per Share ASC 260, Earnings Per Share , requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity. Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested restricted stock units and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore, basic and diluted net loss per share were the same for all periods presented. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the six months ended June 30, 2022 and 2021, respectively, because to do so would be anti-dilutive (in common equivalent shares): As of June 30, 2022 2021 Options to purchase common stock 423,317 551,891 Unvested restricted stock awards 891 7,118 Unvested restricted stock units 125,000 31,146 Preferred stock conversion to common stock 1,363,636 — Warrants to purchase common stock 21,359,809 2,402,442 Total 23,272,653 2,992,597 Adoption of Recent Accounting Pronouncements The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures there are sufficient controls in place to ascertain the Company’s consolidated financial statements properly reflect the change. In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”, which simplifies the accounting for convertible instruments by eliminating the requirement to separate embedded conversion features from the host contract when the conversion features are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or do not result in substantial premiums accounted for as paid-in capital. By removing the separation model, a convertible debt instrument will be reported as a single liability instrument with no separate accounting for embedded conversion features. This new standard also removes certain settlement conditions required for contracts to qualify for equity classification and simplifies the diluted earnings per share calculations by requiring an entity use the if-converted method and the effect of potential share settlement be included in diluted earnings per share calculations. This new standard will be effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company is currently assessing the impact of adopting this standard on the consolidated financial statements.

Revenue Recognition

Revenue Recognition	6 Months Ended
Revenue Recognition	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle: • Step 1: Identify the contract with the customer • Step 2: Identify the performance obligations in the contract • Step 3: Determine the transaction price • Step 4: Allocate the transaction price to the performance obligations in the contract • Step 5: Recognize revenue when the company satisfies a performance obligation Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer. Nature of goods and services The following is a description of principal activities from which the Company generates its revenue. Product sales – The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach. Drug and dialysis concentrate products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales. For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales. In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time control of the product transfers to the customer. The Company received upfront fees under five distribution and license agreements that have been deferred as a contract liability. The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (“Wanbang”), Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), Jeil Pharmaceutical Co., Ltd. ("Jeil Pharma") and Drogsan Pharmaceuticals ("Drogsan Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India, South Korea and Turkey, respectively, to determine regulatory approval was probable as of the execution of the agreement. The amounts received from Baxter Healthcare Corporation (“Baxter”) are recognized as revenue at the point in time the estimated product sales under the agreement occur. For the business under the Company’s Distribution Agreement with Baxter (the “Baxter Agreement”) and for the majority of the Company’s international customers, the Company recognizes revenue at the shipping point, which is generally the Company’s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while distributor payment terms average 45 days. Disaggregation of revenue Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of U.S. dollars ($) Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Products By Geographic Area Total U.S. Rest of World Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 482 $ 209 $ 273 $ 641 $ 368 $ 273 License Fee – Over time 65 — 65 127 — 127 Total Drug Products 547 209 338 768 368 400 Concentrate Products Product Sales – Point-in-time 17,655 15,906 1,749 33,082 29,715 3,367 License Fee – Over time 480 480 — 956 956 — Total Concentrate Products 18,135 16,386 1,749 34,038 30,671 3,367 Net Revenue $ 18,682 $ 16,595 $ 2,087 $ 34,806 $ 31,039 $ 3,767 In thousands of U.S. dollars ($) Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 Products By Geographic Area Total U.S. Rest of World Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 215 $ 215 $ — $ 439 $ 439 $ — License Fee – Over time 58 — 58 117 — 117 Total Drug Products 273 215 58 556 439 117 Concentrate Products Product Sales – Point-in-time 14,379 13,026 1,353 29,084 26,227 2,857 License Fee – Over time 485 485 — 971 971 — Total Concentrate Products 14,864 13,511 1,353 30,055 27,198 2,857 Net Revenue $ 15,137 $ 13,726 $ 1,411 $ 30,611 $ 27,637 $ 2,974 Contract balances The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers. In thousands of U.S. dollars ($) June 30, 2022 December 31, 2021 Receivables, which are included in "Trade and other receivables" $ 8,090 $ 5,913 Contract liabilities $ 7,274 $ 8,157 There were no impairment losses recognized related to any receivables arising from the Company’s contracts with customers for the three and six months ended June 30, 2022 and 2021. For the three and six months ended June 30, 2022 and June 30, 2021, the Company did not recognize any material bad-debt expense. There were no material contract assets recorded on the condensed consolidated balance sheet as of June 30, 2022 and December 31, 2021. The Company does not generally accept returns of its concentrate products and no material reserve for returns of concentrate products was established as of June 30, 2022 or December 31, 2021. The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products Transaction price allocated to remaining performance obligations For the three and six months ended June 30, 2022, revenue recognized from performance obligations related to prior periods was not material. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced, and contracts with variable consideration related to undelivered performance obligations, totaled $7.3 million as of June 30, 2022. The amount relates primarily to upfront payments and consideration received from customers in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations having original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled minimum commitments related to the Baxter Agreement are product sales of $4.3 million as of June 30, 2022, which is amortized ratably through expiration of the Baxter Agreement on October 2, 2024.

Investments - Available-for-Sal

Investments - Available-for-Sale	6 Months Ended
Investments - Available-for-Sale	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Investments - Available-for-Sale	Investments - Available-for-Sale As of June 30, 2022, all investment available-for-sale securities have been liquidated. Investments available-for-sale consisted of the following as of December 31, 2021 (table in thousands): December 31, 2021 Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Fair Value Available-for-Sale Securities Bonds $ 9,143 $ 1 $ — $ 14 $ 9,158 The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 Fair Value Measurements. As of December 31, 2021, the amortized cost and estimated fair value of our available-for-sale securities were due within one year.

Inventory

Inventory	6 Months Ended
Inventory	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventory	Inventory Components of inventory, net of reserves, as of June 30, 2022 and December 31, 2021 are as follows (table in thousands): June 30, December 31, Raw Materials $ 4,377 $ 3,434 Work in Process 285 201 Finished Goods 1,990 1,964 Total $ 6,652 $ 5,599 As of June 30, 2022, the Company classified $1.5 million of inventory as non-current, all of which was related to TRIFERIC ® or the active pharmaceutical ingredient and raw materials for TRIFERIC ® . As of June 30, 2022, the total TRIFERIC ® inventory net of reserve was $1.5 million. The $1.5 million net value of TRIFERIC ® inventory consisted of $0.3 million of TRIFERIC ® (dialysate) finished goods with expiration dates ranging from July 2022 to December 2023, $0.4 million of TRIFERIC ® API with an estimated useful life extending through 2023, and $0.9 million of raw materials for TRIFERIC ® with an estimated useful life of 25 years.

Property and Equipment

Property and Equipment	6 Months Ended
Property and Equipment	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment As of June 30, 2022 and December 31, 2021, the Company’s property and equipment consisted of the following (table in thousands): June 30, December 31, Leasehold Improvements $ 1,250 $ 1,204 Machinery and Equipment 5,874 5,864 Information Technology & Office Equipment 1,845 1,845 Laboratory Equipment 660 676 9,629 9,589 Accumulated Depreciation (7,340) (7,103) Property and Equipment, net $ 2,289 $ 2,486 Depreciation expense for three months ended June 30, 2022 and 2021 was $0.1 million and $0.2 million, respectively. Depreciation expense for six months end June 30, 2022 and 2021 was $0.3 million and $0.4 million, respectively.

Accrued Liabilities

Accrued Liabilities	6 Months Ended
Accrued Liabilities	Jun. 30, 2022
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities as of June 30, 2022 and December 31, 2021 consisted of the following (table in thousands): June 30, December 31, Accrued Research & Development Expense $ 110 $ 366 Accrued Compensation and Benefits 2,439 1,791 Accrued Unvouchered Receipts 385 796 Accrued Workers Compensation 172 382 Other Accrued Liabilities 1,554 1,755 Total Accrued Liabilities $ 4,660 $ 5,090

Deferred Revenue

Deferred Revenue	6 Months Ended
Deferred Revenue	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Deferred Revenue	Deferred Revenue In October 2014, the Company entered into the Baxter Agreement, which has a term of 10 years and received an upfront fee of $20 million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Distribution Agreement. The Company recognized revenue of approximately $0.5 million and $1.0 million for each of the three and six months ended June 30, 2022 and 2021, respectively. Deferred revenue related to the Baxter Agreement totaled $4.3 million as of June 30, 2022 and $5.2 million as of December 31, 2021. In 2016, the Company entered into a distribution agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $4.0 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $0.1 million during each of the three and six months ended June 30, 2022 and 2021. Deferred revenue related to the Wanbang Agreement totaled $2.4 million as of June 30, 2022 and $2.5 million as of December 31, 2021. In January 2020, the Company entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize TRIFERIC ® (dialysate) (ferric pyrophosphate citrate) in India. In consideration for the license, the Company received an upfront fee of $0.1 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $2,500 and $5,000 for each of the three and six months ended June 30, 2022 and 2021, respectively. Deferred revenue related to the Sun Pharma Agreement totaled $75,000 and $80,000 as of June 30, 2022 and December 31, 2021, respectively. In September 2020, the Company entered into a license and supply agreements with Jeil Pharma (the "Jeil Pharma Agreements"), for the rights to commercialize TRIFERIC ® (dialysate) (ferric pyrophosphate citrate) in South Korea. In consideration for the license, the Company received an upfront fee of $0.2 million. In May 2022, Jeil Pharma obtained regulatory approval in South Korea and paid the Company $0.2 million in consideration of reaching the milestone. The upfront fee and milestone payments were recorded as deferred revenue and are being recognized as revenue based on the agreement term. The Company recognized revenue of $2,500 and $7,800 for the three and six months ended June 30, 2022, respectively, and $2,500 and $5,000 for the three and six months ended June 30, 2021, respectively. Deferred revenue related to the Jeil Pharma Agreement totaled approximately $0.4 million and $0.2 million as of June 30, 2022 and December 31, 2021 respectively. In June 2021, the Company entered into license and supply agreements with Drogsan Pharma (the "Drogsan Agreements"), for the rights to commercialize TRIFERIC ® (dialysate) and TRIFERIC ® AVNU in Turkey. In consideration for the license, the Company received an upfront fee of $0.15 million. The upfront fee was recorded as deferred revenue and will be recognized as revenue based on the agreement term. The Company recognized revenue of $3,750 and $7,500 for the three and six months ended June 30, 2022 and 2021, respectively. Deferred revenue related to the Drogsan Agreements totaled approximately $0.14 million as of each of June 30, 2022 and December 31, 2021.

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
Stockholders’ Equity	Jun. 30, 2022
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Reverse Stock Split On May 9, 2022, the stockholders of the Company authorized our Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. Preferred Stock On April 6, 2022, the Company and DaVita entered into the SPA, which provided for the issuance by the Company of up to $15 million of preferred stock to DaVita. On April 6, 2022, the Company issued 7,500 shares of Series X Preferred Stock for gross proceeds of $7.5 million. On June 2, 2022, the Company met the conditions for the Second Tranche through a Registered Direct and Private Placement Offering by raising $15 million in additional capital. As a result, on June 16, 2022 the Company issued an additional 7,500 shares of the Series X Preferred Stock to DaVita for gross proceeds of $7.5 million. The Series X Preferred Stock was issued for a price of $1,000 per share (the "Face Amount"), subject to accretion at a rate of 1% per annum, compounded annually. If the Company’s common stock trades above $22.00 for a period of 30 calendar days, the accretion will thereafter cease. The Series X Convertible Preferred Stock is convertible to common stock at rate equal to the Face Amount, divided by a conversion price of $11.00 per share (subject to adjustment for future stock splits, reverse stock splits and similar recapitalization events). As a result, each share of Series X Preferred Stock will initially convert into approximately 91 shares of common stock. DaVita’s right to convert to common stock is subject to a beneficial ownership limitation, which is initially set at 9.9% of the outstanding common stock, which limitation may be reset (not to exceed 19.9%) at DaVita’s option and upon providing prior written notice to the Company. In addition, any debt financing is limited by the terms of our Securities Purchase Agreement with DaVita. Specifically, until DaVita owns less than 50% of its investment, the Company may only incur additional debt in the form of a purchase money loan, a working capital line of up to $5 million or to refinance existing debt, unless DaVita consents. Additionally, the Series X Preferred Stock has a deemed liquidation event and redemption clause which could be triggered if the sale of all or substantially all of the Company's assets relating to the Company's dialysis concentrates business line. Since the Series X Preferred Stock may be redeemed if certain assets are sold at the option of the holder, but is not mandatorily redeemable, the preferred stock has been classified as permanent equity and initially recognized at fair value of $15 million (the proceeds on the date of issuance) less issuance costs of $0.1 million, resulting in an initial value of $14.9 million. The Company will assess at each reporting period whether conditions have changed to now meet the mandatorily redemptive definition which could trigger liability classification. As of June 30, 2022 and December 31, 2021, there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and 15,000 and nil shares of preferred stock issued and outstanding, respectively. Common Stock As of June 30, 2022 and December 31, 2021, there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 9,407,296 and 8,544,225 shares issued and outstanding, respectively. Controlled Equity Offering On April 8, 2022, the Company entered into the Sales Agreement with Cantor Fitzgerald & Co. as Agent, pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended, pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the SEC on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022. In May 2022, the Company sold 7,500 shares of its common stock pursuant to the Sales Agreement for gross proceeds of $15,135, at a weighted average selling price of approximately $2.02. The Company paid $378 in commissions and offering fees related to the sale of shares of common stock. Under the RD Purchase Agreement and the PIPE Purchase Agreement discussed below, the Company has agreed not to make any sales under any at-the-market offering facility, including pursuant to the Sales Agreement, until at least January 1, 2023 (or until such later time when the Company is permitted to make additional sales under Instruction I.B.6 to Form S-3). Registered Direct Offering On May 30, 2022, the Company entered into the RD Purchase Agreement with the Purchaser named therein, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and pre-funded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant is equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share. A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrants to the extent the holder would own more than 9.99% of the Company’s outstanding common stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrant. The RD Purchase Agreement contains customary representations and warranties and agreements of the Company and the Purchaser and customary indemnification rights and obligations of the parties. Private Placement Also on May 30, 2022, concurrently with the Offering, the Company entered into the PIPE Purchase Agreement relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share. In connection with the Private Placement, the Company entered into a Registration Rights Agreement with the Purchaser, dated as of June 2, 2022 (the “RRA”). Pursuant to the RRA, the Company was required to prepare and file a registration statement with the SEC no later than July 1, 2022, and to use its reasonable best efforts to have the registration statement declared effective as promptly as possible, subject to certain specified penalties if timely effectiveness is not achieved. The Company filed a registration statement on June 22, 2022 which became effective on July 5, 2022. The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses. Subject to certain ownership limitations, the PIPE Warrants are exercisable upon issuance. The Company has accounted for the common stock related to the Offering and Private Placement as equity on the accompanying consolidated balance sheets as of June 30, 2022. The amount allocated to common stock was $2.0 million. This allocation is equal to the total proceeds of $15.0 million less the amount allocated to Warrants of $12.9 million and is also net of the direct and incremental costs associated with the Offering and Private Placement of $0.1 million. The Black-Scholes pricing model was used to calculate the value of Warrants relating to the Offering and Private Placement.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
Stock-Based Compensation	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The Company recognized total stock-based compensation expense during the three and six months ended June 30, 2022 and 2021 as follows (table in thousands): Three Months Ended Six Months Ended 2022 2021 2022 2021 Service-based awards: Restricted stock units $ 26 $ 78 $ 37 $ 182 Stock option awards 72 344 272 735 98 422 309 917 Performance-based awards: Restricted stock awards — — (391) (390) Stock option awards — 11 — (330) — 11 (391) (720) Total $ 98 $ 433 $ (82) $ 197 Performance Based Restricted Stock A summary of the Company’s restricted stock awards during the six months ended June 30, 2022 is as follows: Number of Shares Weighted Average Unvested at January 1, 2022 7,118 $ 62.70 Forfeited (6,227) $ 62.70 Unvested at June 30, 2022 891 $ 62.70 A summary of the Company’s restricted stock awards during the six months ended June 30, 2021 is as follows: Number of Shares Weighted Average Unvested at January 1, 2021 13,345 $ 62.70 Forfeited (6,227) $ 62.70 Unvested at June 30, 2021 7,118 $ 62.70 The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months. As of June 30, 2022, unvested restricted stock awards of 891 were related to performance-based awards. The forfeited performance-based restricted stock awards of 6,227 was due to the resignation of the Company's Chief Development Officer on March 25, 2022. These forfeited awards reduced stock-based compensation expense by $0.4 million. As of June 30, 2021, unvested restricted stock awards of 7,118 were related to performance-based awards. The forfeited performance-based restricted stock awards of 6,227 was due to the termination of the Company's former Chief Science Officer on January 19, 2021. These forfeited awards reduced stock-based compensation expense by $0.4 million. Service-Based Restricted Stock Units A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2022 is as follows: Number of Shares Weighted Average Unvested at January 1, 2022 29,289 $ 12.87 Granted 125,000 1.47 Vested (23,515) 11.33 Forfeited (5,774) 19.00 Unvested at June 30, 2022 125,000 $ 1.47 A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2021 is as follows: Number of Shares Weighted Average Unvested at January 1, 2021 24,136 $ 28.60 Granted 28,186 9.90 Vested (1,042) 52.91 Forfeited (20,134) 26.18 Unvested at June 30, 2021 31,146 $ 12.87 The fair value of service based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1 to 3 years. Stock-based compensation expense of $25,554 and $37,417 was recognized for the three and six months ended June 30, 2022, respectively. Stock-based compensation expense of $0.1 million and $0.2 million was recognized for the three and six months ended June 30, 2021, respectively. As of June 30, 2022, the unrecognized stock-based compensation expense was $0.1 million, which is expected to be recognized over an estimated weighted average remaining term of less than 1 year. Service-Based Stock Options The fair value of the service-based stock options granted for the six months ended June 30, 2022 were based on the following assumptions: June 30, Exercise price $4.12 Expected stock price volatility 76.2% Risk-free interest rate 1.98% Term (years) 6.5 A summary of the Company’s service-based stock option activity for the six months ended June 30, 2022 is as follows: Shares Weighted Weighted Aggregate Outstanding at January 1, 2022 528,591 $ 32.01 7.5 $ — Granted 909 4.07 9.5 — Forfeited (24,488) 15.00 — — Expired (81,695) 83.32 — — Outstanding at June 30, 2022 423,317 $ 23.03 7.8 $ — Exercisable at June 30, 2022 227,412 $ 31.19 7.2 $ — A summary of the Company’s service-based stock option activity for the six months ended June 30, 2021 is as follows: Shares Weighted Weighted Aggregate Outstanding at January 1, 2021 519,814 $ 50.05 6.6 $ — Granted 138,378 10.56 6.0 — Forfeited (25,251) 27.72 — — Expired (115,141) 80.85 — — Outstanding at June 30, 2021 517,800 $ 33.77 7.8 $ 5,000 Exercisable at June 30, 2021 217,040 $ 57.75 5.8 $ — The aggregate intrinsic value in the table above is calculated as the difference between the closing price of the Company's common stock and the exercise price of the stock options that had strike prices below the closing price. During the six months ended June 30, 2022, the Company granted stock options to purchase up to 909 shares of common stock to certain employees. During the six months ended June 30, 2022, 24,488 shares were forfeited and 81,695 shares expired. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly. Stock-based compensation expense recognized for service-based stock options was $0.1 million and $0.3 million for the three and six months ended June 30, 2022, respectively. Stock-based compensation expense recognized for service-based stock options was $0.3 million and $0.7 million for the three and six months ended June 30, 2021, respectively. As of June 30, 2022, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $0.7 million, which is expected to be recognized over an estimated weighted average remaining term of 3.3 years.

Licensing Agreements

Licensing Agreements	6 Months Ended
Licensing Agreements	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Licensing Agreements	Licensing Agreements Product License Agreements The Company is a party to a Licensing Agreement between the Company and Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our TRIFERIC ® product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak and Dr. Ajay Gupta, a former Officer of the Company. Pursuant to the MSA, the parties entered into three additional agreements described below related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak. As of June 30, 2022, the Company has accrued $77,900 relating to certain IP reimbursement expenses and certain sublicense royalty fees and is included within accrued liabilities on the condensed consolidated balance sheet. Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the “Charak Amendment”), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales by the Company of products developed under the license, which includes the Company’s TRIFERIC ® product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis. Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. TRIFERIC ® , dated as of October 7, 2018 (the “IV Agreement”), under which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis. Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN TRIFERIC ® , dated as of October 7, 2018 (the “TPN Agreement”), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain TPN products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis. The potential milestone payments are not yet considered probable, and no milestone payments have been accrued at June 30, 2022.

Leases

Leases	6 Months Ended
Leases	Jun. 30, 2022
Leases [Abstract]
Leases	Leases Rockwell leases its production facilities and administrative offices as well as certain equipment used in its operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to six years. Rockwell occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. Rockwell also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2023. In addition, Rockwell occupied 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on October 31, 2024. This lease was subleased on December 15, 2021 with an expiration date of October 31, 2024. At June 30, 2022, the Company had operating and finance lease liabilities of $6.9 million and right-of-use assets of $6.7 million, which are included in the consolidated balance sheet. At December 31, 2021, the Company had operating lease liabilities of $7.9 million and right-of-use assets of $7.7 million, which are included in the consolidated balance sheet. The following summarizes quantitative information about the Company’s operating leases (table in thousands): Three Months Ended June 30, 2022 Three Months Ended June 30, 2021 Six Months Ended June 30, 2022 Six Months Ended June 30, 2021 Operating leases Operating lease cost $ 431 $ 432 $ 880 $ 851 Variable lease cost 92 90 187 192 Operating lease expense 523 522 1,067 1,043 Finance leases Amortization of right-of-use assets 141 67 282 112 Interest on lease obligations 45 20 92 33 Finance lease expense 186 87 374 145 Short-term lease rent expense 4 4 8 8 Total rent expense $ 713 $ 613 $ 1,449 $ 1,196 Other information Operating cash flows from operating leases $ 447 $ 428 $ 911 $ 853 Operating cash flows from finance leases $ 45 $ 21 $ 92 $ 34 Financing cash flows from finance leases $ 119 $ 56 $ 237 $ 93 Right of use assets exchanged for operating lease liabilities $ — $ 1,476 $ — $ 3,371 Right of use assets exchanged for finance lease liabilities $ — $ 316 $ — $ 777 Weighted-average remaining lease term – operating leases 3.2 3.5 3.2 3.5 Weighted-average remaining lease term – finance leases 4.9 5.5 4.9 5.5 Weighted-average discount rate – operating leases 6.3 % 6.2 % 6.3 % 6.2 % Weighted-average discount rate – finance leases 6.4 % 5.5 % 6.4 % 5.5 % Future minimum rental payments under operating lease agreements are as follows (in thousands): Operating Finance Year ending December 31, 2022 (remaining) $ 861 $ 331 Year ending December 31, 2023 1,456 669 Year ending December 31, 2024 1,114 672 Year ending December 31, 2025 637 676 Year ending December 31, 2026 260 666 Remaining future payments 120 310 Total $ 4,448 $ 3,324 Less present value discount (420) (470) Operating and finance lease liabilities $ 4,028 $ 2,854
Leases	Leases Rockwell leases its production facilities and administrative offices as well as certain equipment used in its operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to six years. Rockwell occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. Rockwell also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2023. In addition, Rockwell occupied 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on October 31, 2024. This lease was subleased on December 15, 2021 with an expiration date of October 31, 2024. At June 30, 2022, the Company had operating and finance lease liabilities of $6.9 million and right-of-use assets of $6.7 million, which are included in the consolidated balance sheet. At December 31, 2021, the Company had operating lease liabilities of $7.9 million and right-of-use assets of $7.7 million, which are included in the consolidated balance sheet. The following summarizes quantitative information about the Company’s operating leases (table in thousands): Three Months Ended June 30, 2022 Three Months Ended June 30, 2021 Six Months Ended June 30, 2022 Six Months Ended June 30, 2021 Operating leases Operating lease cost $ 431 $ 432 $ 880 $ 851 Variable lease cost 92 90 187 192 Operating lease expense 523 522 1,067 1,043 Finance leases Amortization of right-of-use assets 141 67 282 112 Interest on lease obligations 45 20 92 33 Finance lease expense 186 87 374 145 Short-term lease rent expense 4 4 8 8 Total rent expense $ 713 $ 613 $ 1,449 $ 1,196 Other information Operating cash flows from operating leases $ 447 $ 428 $ 911 $ 853 Operating cash flows from finance leases $ 45 $ 21 $ 92 $ 34 Financing cash flows from finance leases $ 119 $ 56 $ 237 $ 93 Right of use assets exchanged for operating lease liabilities $ — $ 1,476 $ — $ 3,371 Right of use assets exchanged for finance lease liabilities $ — $ 316 $ — $ 777 Weighted-average remaining lease term – operating leases 3.2 3.5 3.2 3.5 Weighted-average remaining lease term – finance leases 4.9 5.5 4.9 5.5 Weighted-average discount rate – operating leases 6.3 % 6.2 % 6.3 % 6.2 % Weighted-average discount rate – finance leases 6.4 % 5.5 % 6.4 % 5.5 % Future minimum rental payments under operating lease agreements are as follows (in thousands): Operating Finance Year ending December 31, 2022 (remaining) $ 861 $ 331 Year ending December 31, 2023 1,456 669 Year ending December 31, 2024 1,114 672 Year ending December 31, 2025 637 676 Year ending December 31, 2026 260 666 Remaining future payments 120 310 Total $ 4,448 $ 3,324 Less present value discount (420) (470) Operating and finance lease liabilities $ 4,028 $ 2,854

Loans and Security Agreement

Loans and Security Agreement	6 Months Ended
Loans and Security Agreement	Jun. 30, 2022
Debt Disclosure [Abstract]
Loans and Security Agreement	Loan and Security Agreement On March 16, 2020, the Company and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $5.0 million or a third tranche of $7.5 million, which were tied to the achievement of certain milestones by a specific date. Net draw down proceeds were $21.2 million with closing costs of $1.3 million. In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $18.15 per share or (ii) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 43,388 shares of the Company’s common stock at an exercise price of $18.15 per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $0.5 million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model. The Company is entitled to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9%. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For the three months ended June 30, 2022 and 2021, interest expense amounted to $0.4 million and $0.6 million, respectively. For the six months ended June 30, 2022 and 2021, interest expense amounted to $0.8 million and $1.2 million, respectively. The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds are used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of TRIFERIC ® , with the latter beginning with the period ending December 31, 2020. The Company cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. The Company's ability to comply with these covenants may be adversely affected by events beyond its control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants in the future. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance. However, the Company may not be able to mutually agree with Innovatus on appropriate remedies to cure a future breach of a covenant, which could give rise to an event of default. If the Company is unable to avoid an event of default, any required repayments could have an adverse effect on its liquidity. In September 2021, the Company entered into an amendment to the Loan Agreement in which the Company, in exchange for Innovatus lowering the sales covenants, agreed to (i) prepay an aggregate principal amount of $7,500,000 in ten installments commencing on December 1, 2021; (ii) pay an additional prepayment premium of 5% on prepaid amounts if the Company elects to prepay all outstanding Term Loans on or before September 24, 2023 and (iii) maintain minimum liquidity of no less than $5,000,000 if the aggregate principal amount of Term Loans is greater than $15,000,000 pursuant to the liquidity covenant in the Loan Agreement. On March 31, 2022, the Collateral Agent and Lenders consented to the delivery to Collateral Agent and Lenders of its annual audited financial statements for the fiscal year 2021 by April 15, 2022 as opposed to within 90 days of December 31, 2021, as required pursuant to Loan Agreement. As of June 30, 2022, the Company was in compliance with all covenants under the Loan Agreement. As of June 30, 2022, the outstanding balance of the Term Loan was $15.5 million, net of unamortized issuance costs and discount of $1.0 million. The following table reflects the schedule of principal payments on the Term Loan as of June 30, 2022 (in thousands): Principal Payments 2022 $ 2,500 2023 6,000 2024 6,000 2025 2,000 $ 16,500

Insurance Financing Note Payabl

Insurance Financing Note Payable	6 Months Ended
Insurance Financing Note Payable	Jun. 30, 2022
Debt Disclosure [Abstract]
Insurance Financing Note Payable	Insurance Financing Note PayableOn June 2, 2022, the Company entered into a short-term note payable for $1.5 million, bearing interest at 5.40% per annum to finance various insurance policies. Principal and interest payments related to this note began on July 3, 2022 and were paid on a straight-line amortization over 9 months with the final payment due on March 3, 2023. As of June 30, 2022, the Company's insurance note payable balance was $1.5 million.

Subsequent Events

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On July 14, 2022, 952,897 Pre-Funded Warrants to purchase common stock pursuant the SPA entered into on May 30, 2022 were exercised. The exercise price of each Pre-Funded Warrant is $0.0001 per share and resulted in gross proceeds of $95.29 (See Note 10 for more detail on the SPA). On July 14, 2022, the Company filed a Registration Statement on Form S-3 under the Securities Act of 1933 to register the shares of common stock underlying the shares of Series X Preferred Stock issued to DaVita on April 6, 2022 and June 16, 2022. The Form S-3 was declared effective by the SEC on July 22, 2022 (See Note 10 for more detail). On August 10, 2022, 315,000 Pre-Funded Warrants to purchase common stock pursuant the SPA entered into on May 30, 2022 were exercised. The exercise price of each Pre-Funded Warrant is $0.0001 per share and resulted in gross proceeds of $31.50 (See Note 10 for more detail on the SPA).

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
Reverse Stock Split	Reverse Stock Split On May 9, 2022, the stockholders of the Company authorized our Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series X convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to account for the effect of the reverse stock split for the three and six month periods ended June 30, 2022 and 2021, respectively, and the balance sheet at June 30, 2022 and December 31, 2021.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Leases	Leases The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases . Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.
Loss Per Share	Loss Per Share ASC 260, Earnings Per Share , requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity. Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested restricted stock units and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore, basic and diluted net loss per share were the same for all periods presented. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the six months ended June 30, 2022 and 2021, respectively, because to do so would be anti-dilutive (in common equivalent shares):
Adoption of Recent Accounting Pronouncements	Adoption of Recent Accounting Pronouncements The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures there are sufficient controls in place to ascertain the Company’s consolidated financial statements properly reflect the change. In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”, which simplifies the accounting for convertible instruments by eliminating the requirement to separate embedded conversion features from the host contract when the conversion features are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or do not result in substantial premiums accounted for as paid-in capital. By removing the separation model, a convertible debt instrument will be reported as a single liability instrument with no separate accounting for embedded conversion features. This new standard also removes certain settlement conditions required for contracts to qualify for equity classification and simplifies the diluted earnings per share calculations by requiring an entity use the if-converted method and the effect of potential share settlement be included in diluted earnings per share calculations. This new standard will be effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company is currently assessing the impact of adopting this standard on the consolidated financial statements.

Basis of Presentation, Summar_3

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Potentially Dilutive Securities	The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the six months ended June 30, 2022 and 2021, respectively, because to do so would be anti-dilutive (in common equivalent shares): As of June 30, 2022 2021 Options to purchase common stock 423,317 551,891 Unvested restricted stock awards 891 7,118 Unvested restricted stock units 125,000 31,146 Preferred stock conversion to common stock 1,363,636 — Warrants to purchase common stock 21,359,809 2,402,442 Total 23,272,653 2,992,597

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
Revenue Recognition (Tables)	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of U.S. dollars ($) Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Products By Geographic Area Total U.S. Rest of World Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 482 $ 209 $ 273 $ 641 $ 368 $ 273 License Fee – Over time 65 — 65 127 — 127 Total Drug Products 547 209 338 768 368 400 Concentrate Products Product Sales – Point-in-time 17,655 15,906 1,749 33,082 29,715 3,367 License Fee – Over time 480 480 — 956 956 — Total Concentrate Products 18,135 16,386 1,749 34,038 30,671 3,367 Net Revenue $ 18,682 $ 16,595 $ 2,087 $ 34,806 $ 31,039 $ 3,767 In thousands of U.S. dollars ($) Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 Products By Geographic Area Total U.S. Rest of World Total U.S. Rest of World Drug Revenues Product Sales – Point-in-time $ 215 $ 215 $ — $ 439 $ 439 $ — License Fee – Over time 58 — 58 117 — 117 Total Drug Products 273 215 58 556 439 117 Concentrate Products Product Sales – Point-in-time 14,379 13,026 1,353 29,084 26,227 2,857 License Fee – Over time 485 485 — 971 971 — Total Concentrate Products 14,864 13,511 1,353 30,055 27,198 2,857 Net Revenue $ 15,137 $ 13,726 $ 1,411 $ 30,611 $ 27,637 $ 2,974
Contract Balances	The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers. In thousands of U.S. dollars ($) June 30, 2022 December 31, 2021 Receivables, which are included in "Trade and other receivables" $ 8,090 $ 5,913 Contract liabilities $ 7,274 $ 8,157

Investments - Available-for-S_2

Investments - Available-for-Sale (Tables)	6 Months Ended
Investments - Available-for-Sale (Tables)	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Investments Available-for-Sale	Investments available-for-sale consisted of the following as of December 31, 2021 (table in thousands): December 31, 2021 Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Fair Value Available-for-Sale Securities Bonds $ 9,143 $ 1 $ — $ 14 $ 9,158

Inventory (Tables)

Inventory (Tables)	6 Months Ended
Inventory (Tables)	Jun. 30, 2022
Inventory Disclosure [Abstract]
Schedule Components of Inventory	Components of inventory, net of reserves, as of June 30, 2022 and December 31, 2021 are as follows (table in thousands): June 30, December 31, Raw Materials $ 4,377 $ 3,434 Work in Process 285 201 Finished Goods 1,990 1,964 Total $ 6,652 $ 5,599

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
Property and Equipment (Tables)	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Major Classes of Property and Equipment	As of June 30, 2022 and December 31, 2021, the Company’s property and equipment consisted of the following (table in thousands): June 30, December 31, Leasehold Improvements $ 1,250 $ 1,204 Machinery and Equipment 5,874 5,864 Information Technology & Office Equipment 1,845 1,845 Laboratory Equipment 660 676 9,629 9,589 Accumulated Depreciation (7,340) (7,103) Property and Equipment, net $ 2,289 $ 2,486

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
Accrued Liabilities (Tables)	Jun. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities as of June 30, 2022 and December 31, 2021 consisted of the following (table in thousands): June 30, December 31, Accrued Research & Development Expense $ 110 $ 366 Accrued Compensation and Benefits 2,439 1,791 Accrued Unvouchered Receipts 385 796 Accrued Workers Compensation 172 382 Other Accrued Liabilities 1,554 1,755 Total Accrued Liabilities $ 4,660 $ 5,090

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
Stock-Based Compensation (Tables)	Jun. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of Total Stock-Based Compensation Expense	The Company recognized total stock-based compensation expense during the three and six months ended June 30, 2022 and 2021 as follows (table in thousands): Three Months Ended Six Months Ended 2022 2021 2022 2021 Service-based awards: Restricted stock units $ 26 $ 78 $ 37 $ 182 Stock option awards 72 344 272 735 98 422 309 917 Performance-based awards: Restricted stock awards — — (391) (390) Stock option awards — 11 — (330) — 11 (391) (720) Total $ 98 $ 433 $ (82) $ 197
Restricted stock awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of Restricted Stock Awards	A summary of the Company’s restricted stock awards during the six months ended June 30, 2022 is as follows: Number of Shares Weighted Average Unvested at January 1, 2022 7,118 $ 62.70 Forfeited (6,227) $ 62.70 Unvested at June 30, 2022 891 $ 62.70 A summary of the Company’s restricted stock awards during the six months ended June 30, 2021 is as follows: Number of Shares Weighted Average Unvested at January 1, 2021 13,345 $ 62.70 Forfeited (6,227) $ 62.70 Unvested at June 30, 2021 7,118 $ 62.70
Restricted stock units - service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of Restricted Stock Awards	A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2022 is as follows: Number of Shares Weighted Average Unvested at January 1, 2022 29,289 $ 12.87 Granted 125,000 1.47 Vested (23,515) 11.33 Forfeited (5,774) 19.00 Unvested at June 30, 2022 125,000 $ 1.47 A summary of the Company’s service-based restricted stock units during the six months ended June 30, 2021 is as follows: Number of Shares Weighted Average Unvested at January 1, 2021 24,136 $ 28.60 Granted 28,186 9.90 Vested (1,042) 52.91 Forfeited (20,134) 26.18 Unvested at June 30, 2021 31,146 $ 12.87
Stock option awards - service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Schedule of Stock Option Assumptions	The fair value of the service-based stock options granted for the six months ended June 30, 2022 were based on the following assumptions: June 30, Exercise price $4.12 Expected stock price volatility 76.2% Risk-free interest rate 1.98% Term (years) 6.5
Schedule of Stock Options Activity	A summary of the Company’s service-based stock option activity for the six months ended June 30, 2022 is as follows: Shares Weighted Weighted Aggregate Outstanding at January 1, 2022 528,591 $ 32.01 7.5 $ — Granted 909 4.07 9.5 — Forfeited (24,488) 15.00 — — Expired (81,695) 83.32 — — Outstanding at June 30, 2022 423,317 $ 23.03 7.8 $ — Exercisable at June 30, 2022 227,412 $ 31.19 7.2 $ — A summary of the Company’s service-based stock option activity for the six months ended June 30, 2021 is as follows: Shares Weighted Weighted Aggregate Outstanding at January 1, 2021 519,814 $ 50.05 6.6 $ — Granted 138,378 10.56 6.0 — Forfeited (25,251) 27.72 — — Expired (115,141) 80.85 — — Outstanding at June 30, 2021 517,800 $ 33.77 7.8 $ 5,000 Exercisable at June 30, 2021 217,040 $ 57.75 5.8 $ —

Leases (Tables)

Leases (Tables)	6 Months Ended
Leases (Tables)	Jun. 30, 2022
Leases [Abstract]
Summary of Lease Costs	The following summarizes quantitative information about the Company’s operating leases (table in thousands): Three Months Ended June 30, 2022 Three Months Ended June 30, 2021 Six Months Ended June 30, 2022 Six Months Ended June 30, 2021 Operating leases Operating lease cost $ 431 $ 432 $ 880 $ 851 Variable lease cost 92 90 187 192 Operating lease expense 523 522 1,067 1,043 Finance leases Amortization of right-of-use assets 141 67 282 112 Interest on lease obligations 45 20 92 33 Finance lease expense 186 87 374 145 Short-term lease rent expense 4 4 8 8 Total rent expense $ 713 $ 613 $ 1,449 $ 1,196 Other information Operating cash flows from operating leases $ 447 $ 428 $ 911 $ 853 Operating cash flows from finance leases $ 45 $ 21 $ 92 $ 34 Financing cash flows from finance leases $ 119 $ 56 $ 237 $ 93 Right of use assets exchanged for operating lease liabilities $ — $ 1,476 $ — $ 3,371 Right of use assets exchanged for finance lease liabilities $ — $ 316 $ — $ 777 Weighted-average remaining lease term – operating leases 3.2 3.5 3.2 3.5 Weighted-average remaining lease term – finance leases 4.9 5.5 4.9 5.5 Weighted-average discount rate – operating leases 6.3 % 6.2 % 6.3 % 6.2 % Weighted-average discount rate – finance leases 6.4 % 5.5 % 6.4 % 5.5 %
Operating Lease Maturities	Future minimum rental payments under operating lease agreements are as follows (in thousands): Operating Finance Year ending December 31, 2022 (remaining) $ 861 $ 331 Year ending December 31, 2023 1,456 669 Year ending December 31, 2024 1,114 672 Year ending December 31, 2025 637 676 Year ending December 31, 2026 260 666 Remaining future payments 120 310 Total $ 4,448 $ 3,324 Less present value discount (420) (470) Operating and finance lease liabilities $ 4,028 $ 2,854
Finance Lease Maturities	Future minimum rental payments under operating lease agreements are as follows (in thousands): Operating Finance Year ending December 31, 2022 (remaining) $ 861 $ 331 Year ending December 31, 2023 1,456 669 Year ending December 31, 2024 1,114 672 Year ending December 31, 2025 637 676 Year ending December 31, 2026 260 666 Remaining future payments 120 310 Total $ 4,448 $ 3,324 Less present value discount (420) (470) Operating and finance lease liabilities $ 4,028 $ 2,854

Loans and Security Agreement (T

Loans and Security Agreement (Tables)	6 Months Ended
Loans and Security Agreement (Tables)	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Principal Payments on Term Loan	The following table reflects the schedule of principal payments on the Term Loan as of June 30, 2022 (in thousands): Principal Payments 2022 $ 2,500 2023 6,000 2024 6,000 2025 2,000 $ 16,500

Description of Business (Detail

Description of Business (Details)	6 Months Ended
Description of Business (Details)	Jun. 30, 2022 ft² facility
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of facilities \| facility	3
Operating space \| ft²	175,000

Liquidity and Capital Resourc_2

Liquidity and Capital Resources (Details)						1 Months Ended	5 Months Ended	6 Months Ended
Liquidity and Capital Resources (Details)	Jun. 16, 2022 USD ($) shares	Jun. 15, 2022 USD ($) shares	Jun. 02, 2022 USD ($)	May 30, 2022 $ / shares shares	Apr. 06, 2022 USD ($) $ / shares shares	May 31, 2022 USD ($) $ / shares shares	Dec. 08, 2021 businessDay $ / shares	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Apr. 08, 2022 USD ($)	Dec. 31, 2021 USD ($)
Liquidity and Going Concern Considerations [Line Items]
Cash and Cash Equivalents								$ 30,780,000			$ 13,280,000
Working capital								28,700,000
Net cash used in operating activities								(15,718,000)	$ (17,433,000)
Minimum cash covenant								10,000,000
Stock issuance costs			$ 100,000					$ 106,000	$ 0
Proceeds from sale of equity, net			14,900,000
Period to regain Nasdaq minimum bid requirements							180 days
Common stock, closing bid price (at least) (in dollars per share) \| $ / shares							$ 1
Number of consecutive business days (minimum) \| businessDay							10
Series X Convertible Preferred Stock
Liquidity and Going Concern Considerations [Line Items]
Consideration received					$ 15,000,000
Stock issuance costs					100,000
Proceeds from sale of equity, net					14,900,000
Registered Direct Offering Warrants
Liquidity and Going Concern Considerations [Line Items]
Number of shares of common stock for which warrant is exercisable (in shares) \| shares				7,788,480
Exercise price of warrant (in dollars per share) \| $ / shares				$ 0.0001
PIPE Purchase Agreement Pre-Funded Warrant
Liquidity and Going Concern Considerations [Line Items]
Number of shares of common stock for which warrant is exercisable (in shares) \| shares				1,267,897
Exercise price of warrant (in dollars per share) \| $ / shares				$ 0.0001
PIPE Purchase Agreement Warrant
Liquidity and Going Concern Considerations [Line Items]
Number of shares of common stock for which warrant is exercisable (in shares) \| shares				9,900,990,000,000
Exercise price of warrant (in dollars per share) \| $ / shares				$ 1.39
Warrant price (dollars per share) \| $ / shares				$ 0.125
Registered Direct Offering
Liquidity and Going Concern Considerations [Line Items]
Number of shares issued \| shares				844,613
Common stock trading price (in dollars per share) \| $ / shares				$ 1.39
Registered Direct Offering \| Registered Direct Offering Warrants
Liquidity and Going Concern Considerations [Line Items]
Exercise price of warrant (in dollars per share) \| $ / shares				$ 0.0001
Cantor Fitzgerald & Co \| Controlled Equity Offering
Liquidity and Going Concern Considerations [Line Items]
Sale of stock, aggregate consideration authorized										$ 12,200,000
Number of shares issued \| shares						7,500
Consideration received						$ 15,135
Weighted-average selling price (dollars per share) \| $ / shares						$ 2.02
Stock issuance costs						$ 378
Da Vita Healthcare Partners Inc \| Share Issuance, Tranche One
Liquidity and Going Concern Considerations [Line Items]
Proceeds from issuance of convertible preferred stock					7,500,000
Da Vita Healthcare Partners Inc \| Share Issuance, Tranche Two
Liquidity and Going Concern Considerations [Line Items]
Proceeds from issuance of convertible preferred stock	$ 7,500,000	$ 7,500,000
Da Vita Healthcare Partners Inc \| Private Placement \| Series X Convertible Preferred Stock
Liquidity and Going Concern Considerations [Line Items]
Sale of stock, aggregate consideration authorized					$ 15,000,000
Consideration received			$ 15,000,000
Common stock trading price (in dollars per share) \| $ / shares					$ 1,000
Da Vita Healthcare Partners Inc \| Private Placement \| Share Issuance, Tranche One \| Series X Convertible Preferred Stock
Liquidity and Going Concern Considerations [Line Items]
Number of shares issued \| shares					7,500
Da Vita Healthcare Partners Inc \| Private Placement \| Share Issuance, Tranche Two \| Series X Convertible Preferred Stock
Liquidity and Going Concern Considerations [Line Items]
Number of shares issued \| shares	7,500	7,500

Basis of Presentation, Summar_4

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Summary of Potentially Dilutive Securities (Details)		6 Months Ended
	May 09, 2022	Jun. 30, 2022 shares	Jun. 30, 2021 shares
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)		23,272,653	2,992,597
Reverse stock split	0.09
Options to purchase common stock
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)		423,317	551,891
Unvested restricted stock awards
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)		891	7,118
Unvested restricted stock units
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)		125,000	31,146
Preferred stock conversion to common stock
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)		1,363,636	0
Warrants to purchase common stock
Net Earnings per Share
Securities excluded from diluted loss per share calculation (in shares)		21,359,809	2,402,442

Revenue Recognition - Nature of

Revenue Recognition - Nature of Goods and Services (Details)	6 Months Ended
	Jun. 30, 2022 agreement
Revenue from Contract with Customer [Abstract]
Number of distribution and license agreements	5
Customers average payment term	30 days
Distributors average payment term	45 days

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Net Revenue	$ 18,682	$ 15,137	$ 34,806	$ 30,611
Drug products
Disaggregation of Revenue [Line Items]
Net Revenue	547	273	768	556
Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	18,135	14,864	34,038	30,055
U.S.
Disaggregation of Revenue [Line Items]
Net Revenue	16,595	13,726	31,039	27,637
U.S. \| Drug products
Disaggregation of Revenue [Line Items]
Net Revenue	209	215	368	439
U.S. \| Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	16,386	13,511	30,671	27,198
Rest of World
Disaggregation of Revenue [Line Items]
Net Revenue	2,087	1,411	3,767	2,974
Rest of World \| Drug products
Disaggregation of Revenue [Line Items]
Net Revenue	338	58	400	117
Rest of World \| Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	1,749	1,353	3,367	2,857
Product Sales – Point-in-time \| Drug product sales
Disaggregation of Revenue [Line Items]
Net Revenue	482	215	641	439
Product Sales – Point-in-time \| Concentrate product sales
Disaggregation of Revenue [Line Items]
Net Revenue	17,655	14,379	33,082	29,084
Product Sales – Point-in-time \| U.S. \| Drug product sales
Disaggregation of Revenue [Line Items]
Net Revenue	209	215	368	439
Product Sales – Point-in-time \| U.S. \| Concentrate product sales
Disaggregation of Revenue [Line Items]
Net Revenue	15,906	13,026	29,715	26,227
Product Sales – Point-in-time \| Rest of World \| Drug product sales
Disaggregation of Revenue [Line Items]
Net Revenue	273	0	273	0
Product Sales – Point-in-time \| Rest of World \| Concentrate product sales
Disaggregation of Revenue [Line Items]
Net Revenue	1,749	1,353	3,367	2,857
License Fee – Over time \| Drug license fee
Disaggregation of Revenue [Line Items]
Net Revenue	65	58	127	117
License Fee – Over time \| Concentrate product license fee
Disaggregation of Revenue [Line Items]
Net Revenue	480	485	956	971
License Fee – Over time \| U.S. \| Drug license fee
Disaggregation of Revenue [Line Items]
Net Revenue	0	0	0	0
License Fee – Over time \| U.S. \| Concentrate product license fee
Disaggregation of Revenue [Line Items]
Net Revenue	480	485	956	971
License Fee – Over time \| Rest of World \| Drug license fee
Disaggregation of Revenue [Line Items]
Net Revenue	65	58	127	117
License Fee – Over time \| Rest of World \| Concentrate product license fee
Disaggregation of Revenue [Line Items]
Net Revenue	$ 0	$ 0	$ 0	$ 0

Revenue Recognition - Contract

Revenue Recognition - Contract Balances (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Receivables, which are included in "Trade and other receivables"	$ 8,090	$ 5,913
Contract liabilities	$ 7,274	$ 8,157

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
Revenue Recognition - Narrative (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Revenue Recognition [Line Items]
Impairment losses	$ 0	$ 0	$ 0	$ 0
Contract assets	0		0		$ 0
Revenue performance obligation	7,300,000		7,300,000
Baxter Healthcare Organization
Revenue Recognition [Line Items]
Revenue performance obligation	4,300,000		4,300,000
Concentrate Products
Revenue Recognition [Line Items]
Reserve for returns	$ 0		$ 0		$ 0

Investments - Available-for-S_3

Investments - Available-for-Sale (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Amortized Cost		$ 9,143
Unrealized Gain		1
Unrealized Loss		0
Accrued Interest		14
Fair Value	$ 0	$ 9,158

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	6 Months Ended
Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory [Line Items]
Raw Materials	$ 4,377	$ 3,434
Work in Process	285	201
Finished Goods	1,990	1,964
Total	6,652	5,599
Inventory, noncurrent	1,481	1,523
Inventory, net	5,171	$ 4,076
Triferic Inventory
Inventory [Line Items]
Raw Materials	900
Inventory, noncurrent	1,500
Inventory, net	$ 1,500
Useful life	25 years
Triferic Dialysate
Inventory [Line Items]
Finished Goods	$ 300
Triferic API
Inventory [Line Items]
Inventory, net	$ 400

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Property and equipment
Gross property and equipment	$ 9,629		$ 9,629		$ 9,589
Accumulated Depreciation	(7,340)		(7,340)		(7,103)
Property and Equipment, net	2,289		2,289		2,486
Depreciation expense	100	$ 200	300	$ 400
Leasehold Improvements
Property and equipment
Gross property and equipment	1,250		1,250		1,204
Machinery and Equipment
Property and equipment
Gross property and equipment	5,874		5,874		5,864
Information Technology & Office Equipment
Property and equipment
Gross property and equipment	1,845		1,845		1,845
Laboratory Equipment
Property and equipment
Gross property and equipment	$ 660		$ 660		$ 676

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued Research & Development Expense	$ 110	$ 366
Accrued Compensation and Benefits	2,439	1,791
Accrued Unvouchered Receipts	385	796
Accrued Workers Compensation	172	382
Other Accrued Liabilities	1,554	1,755
Total Accrued Liabilities	$ 4,660	$ 5,090

Deferred Revenue (Details)

Deferred Revenue (Details) - USD ($)	1 Months Ended					3 Months Ended		6 Months Ended		12 Months Ended
Deferred Revenue (Details) - USD ($)	May 31, 2022	Jun. 30, 2021	Sep. 30, 2020	Jan. 31, 2020	Oct. 31, 2014	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2016	Dec. 31, 2021
Deferred Revenue Arrangement [Line Items]
Deferred revenue						$ 7,274,000		$ 7,274,000			$ 8,157,000
Baxter Healthcare Organization
Deferred Revenue Arrangement [Line Items]
Term of agreement					10 years
Upfront payment					$ 20,000,000
Recognized deferred revenue						500,000	$ 500,000	1,000,000	$ 1,000,000
Deferred revenue						4,300,000		4,300,000			5,200,000
Wanbang Biopharmaceutical
Deferred Revenue Arrangement [Line Items]
Upfront payment										$ 4,000,000
Recognized deferred revenue						100,000	100,000	100,000	100,000
Deferred revenue						2,400,000		2,400,000			2,500,000
Sun Pharma Agreements
Deferred Revenue Arrangement [Line Items]
Upfront payment				$ 100,000
Recognized deferred revenue						2,500	2,500	5,000	5,000
Deferred revenue						75,000		75,000			80,000
Jeil Pharma Agreements
Deferred Revenue Arrangement [Line Items]
Upfront payment			$ 200,000
Recognized deferred revenue						2,500	2,500	7,800	5,000
Deferred revenue						400,000		400,000			200,000
Milestone consideration	$ 200,000
Drogsan Agreements
Deferred Revenue Arrangement [Line Items]
Upfront payment		$ 150,000
Recognized deferred revenue						3,750	$ 3,750	7,500	$ 7,500
Deferred revenue						$ 140,000		$ 140,000			$ 140,000

Stockholders_ Equity (Details)

Stockholders’ Equity (Details)						1 Months Ended	6 Months Ended
Stockholders’ Equity (Details)	Jun. 16, 2022 USD ($) shares	Jun. 15, 2022 USD ($) shares	Jun. 02, 2022 USD ($)	May 30, 2022 $ / shares shares	Apr. 06, 2022 USD ($) $ / shares shares	May 31, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($)	Apr. 08, 2022 USD ($)	Dec. 31, 2021 $ / shares shares
Class of Stock [Line Items]
Preferred shares, shares authorized (in shares) \| shares							2,000,000			2,000,000
Preferred shares, par value (in dollars per share) \| $ / shares							$ 0.0001			$ 0.0001
Preferred shares, shares issued (in shares) \| shares							15,000			0
Preferred shares, shares outstanding (in shares) \| shares							15,000			0
Common shares, shares authorized (in shares) \| shares							170,000,000			170,000,000
Common shares, par value (in dollars per share) \| $ / shares							$ 0.0001			$ 0.0001
Common shares, shares outstanding (in shares) \| shares							9,407,296			8,544,225
Common shares, shares issued (in shares) \| shares							9,407,296			8,544,225
Proceeds from sale of equity, net			$ 14,900,000
Proceeds from the issuance of common stock			2,000,000				$ 15,016,000	$ 0
Proceeds from issuance of warrants			12,900,000
Stock issuance costs			100,000				$ 106,000	$ 0
PIPE Purchase Agreement Warrant
Class of Stock [Line Items]
Number of shares of common stock for which warrant is exercisable (in shares) \| shares				9,900,990,000,000
Exercise price of warrant (in dollars per share) \| $ / shares				$ 1.39
Warrant price (dollars per share) \| $ / shares				$ 0.125
PIPE Purchase Agreement Pre-Funded Warrant
Class of Stock [Line Items]
Number of shares of common stock for which warrant is exercisable (in shares) \| shares				1,267,897
Discount from stock price (dollars per share) \| $ / shares				$ 0.0001
Exercise price of warrant (in dollars per share) \| $ / shares				$ 0.0001
Registered Direct Offering Warrants
Class of Stock [Line Items]
Number of shares of common stock for which warrant is exercisable (in shares) \| shares				7,788,480
Discount from stock price (dollars per share) \| $ / shares				$ 0.0001
Exercise price of warrant (in dollars per share) \| $ / shares				$ 0.0001
Ownership threshold				9.99%
Series X Convertible Preferred Stock
Class of Stock [Line Items]
Interest rate percentage					1%
Common stock trading price (per share) \| $ / shares					$ 22
Common stock trading period					30 years
Conversion price (per share) \| $ / shares					$ 11
Convertible preferred stock (in shares)					91
Outstanding common stock, percentage					9.90%
Outstanding common stock, not to exceed, percentage					19.90%
Percentage of investment owned					50%
Maximum working capital line					$ 5,000,000
Consideration received					15,000,000
Proceeds from sale of equity, net					14,900,000
Stock issuance costs					100,000
Da Vita Healthcare Partners Inc \| Share Issuance, Tranche One
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock					7,500,000
Da Vita Healthcare Partners Inc \| Share Issuance, Tranche Two
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock	$ 7,500,000	$ 7,500,000
Private Placement \| Da Vita Healthcare Partners Inc \| Series X Convertible Preferred Stock
Class of Stock [Line Items]
Sale of stock, aggregate consideration authorized					15,000,000
Sale of stock, capital proceeds threshold					$ 15,000,000
Common stock trading price (in dollars per share) \| $ / shares					$ 1,000
Consideration received			$ 15,000,000
Private Placement \| Da Vita Healthcare Partners Inc \| Series X Convertible Preferred Stock \| Share Issuance, Tranche One
Class of Stock [Line Items]
Number of shares issued \| shares					7,500
Private Placement \| Da Vita Healthcare Partners Inc \| Series X Convertible Preferred Stock \| Share Issuance, Tranche Two
Class of Stock [Line Items]
Number of shares issued \| shares	7,500	7,500
Controlled Equity Offering \| Cantor Fitzgerald & Co
Class of Stock [Line Items]
Sale of stock, aggregate consideration authorized									$ 12,200,000
Number of shares issued \| shares						7,500
Consideration received						$ 15,135
Weighted-average selling price (dollars per share) \| $ / shares						$ 2.02
Stock issuance costs						$ 378
Registered Direct Offering
Class of Stock [Line Items]
Number of shares issued \| shares				844,613
Common stock trading price (in dollars per share) \| $ / shares				$ 1.39
Registered Direct Offering \| Registered Direct Offering Warrants
Class of Stock [Line Items]
Discount from stock price (dollars per share) \| $ / shares				0.0001
Exercise price of warrant (in dollars per share) \| $ / shares				$ 0.0001

Stock-Based Compensation - Shar

Stock-Based Compensation - Share-Based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	$ 98,000	$ 433,000	$ (82,000)	$ 197,000
Service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	98,000	422,000	309,000	917,000
Restricted stock units - service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	25,554	78,000	37,417	182,000
Stock option awards - service based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	72,000	344,000	272,000	735,000
Performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	0	11,000	(391,000)	(720,000)
Restricted stock awards - performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	0	0	(391,000)	(390,000)
Stock option awards - performance based awards
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	$ 0	$ 11,000	$ 0	$ (330,000)

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Awards (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Weighted Average Grant-Date Fair Value
Stock based compensation expenses	$ 98,000	$ 433,000	$ (82,000)	$ 197,000
Restricted stock awards
Weighted Average Grant-Date Fair Value
Vesting period			20 months
Restricted stock awards - performance based awards
Number of Shares
Unvested at beginning of period (in shares)			7,118	13,345
Forfeited (in shares)			(6,227)	(6,227)
Unvested at end of period (in shares)	891	7,118	891	7,118
Weighted Average Grant-Date Fair Value
Unvested at beginning of period (in dollars per share)			$ 62.70	$ 62.70
Forfeited (in dollars per share)			62.70	62.70
Unvested at end of period (in dollars per share)	$ 62.70	$ 62.70	$ 62.70	$ 62.70
Unvested, number of shares (in shares)	891	7,118	891	7,118
Forfeited (in shares)			(6,227)	(6,227)
Stock based compensation expenses	$ 0	$ 0	$ (391,000)	$ (390,000)
Restricted stock units - service based awards
Number of Shares
Unvested at beginning of period (in shares)			29,289	24,136
Granted (in shares)			125,000	28,186
Vested (in shares)			23,515	1,042
Forfeited (in shares)			(5,774)	(20,134)
Unvested at end of period (in shares)	125,000	31,146	125,000	31,146
Weighted Average Grant-Date Fair Value
Unvested at beginning of period (in dollars per share)			$ 12.87	$ 28.60
Granted (in dollars per share)			1.47	9.90
Vested (in dollars per share)			11.33	52.91
Forfeited (in dollars per share)			19	26.18
Unvested at end of period (in dollars per share)	$ 1.47	$ 12.87	$ 1.47	$ 12.87
Unvested, number of shares (in shares)	125,000	31,146	125,000	31,146
Forfeited (in shares)			(5,774)	(20,134)
Stock based compensation expenses	$ 25,554	$ 78,000	$ 37,417	$ 182,000

Stock-Based Compensation - Serv

Stock-Based Compensation - Service Based Restricted Stock Units (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Weighted Average Grant-Date Fair Value
Stock based compensation expenses	$ 98,000	$ 433,000	$ (82,000)	$ 197,000
Restricted stock units - service based awards
Number of Shares
Unvested at beginning of period (in shares)			29,289	24,136
Granted (in shares)			125,000	28,186
Vested (in shares)			(23,515)	(1,042)
Forfeited (in shares)			(5,774)	(20,134)
Unvested at end of period (in shares)	125,000	31,146	125,000	31,146
Weighted Average Grant-Date Fair Value
Unvested at beginning of period (in dollars per share)			$ 12.87	$ 28.60
Granted (in dollars per share)			1.47	9.90
Vested (in dollars per share)			11.33	52.91
Forfeited (in dollars per share)			19	26.18
Unvested at end of period (in dollars per share)	$ 1.47	$ 12.87	$ 1.47	$ 12.87
Stock based compensation expenses	$ 25,554	$ 78,000	$ 37,417	$ 182,000
Unrecognized stock-based compensation expense	$ 100,000		$ 100,000
Unrecognized stock-based compensation expense, weighted average remaining term (in years) (less than)			1 year
Restricted stock units - service based awards \| Minimum
Weighted Average Grant-Date Fair Value
Vesting period			1 year
Restricted stock units - service based awards \| Maximum
Weighted Average Grant-Date Fair Value
Vesting period			3 years

Stock-Based Compensation - Se_2

Stock-Based Compensation - Service Based Stock Options - Fair Value Assumptions (Details) - Stock option awards - service based awards	6 Months Ended
	Jun. 30, 2022 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (in dollars per share)	$ 4.12
Expected stock price volatility	76.20%
Risk-free interest rate	1.98%
Term (years)	6 years 6 months

Stock-Based Compensation - Se_3

Stock-Based Compensation - Service Based Stock Options (Details) - Stock option awards - service based awards - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Shares Underlying Options
Outstanding at the beginning of the period (in shares)	528,591	519,814	519,814
Granted (in shares)	909	138,378
Forfeited (in shares)	(24,488)	(25,251)
Expired (in shares)	(81,695)	(115,141)
Outstanding at the end of the period (in shares)	423,317	517,800	528,591	519,814
Exercisable at end of period (in shares)	227,412	217,040
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)	$ 32.01	$ 50.05	$ 50.05
Granted (in dollars per share)	4.07	10.56
Forfeited (in dollars per share)	15	27.72
Expired (in dollar per share)	83.32	80.85
Outstanding at the end of the period (in dollars per share)	23.03	33.77	$ 32.01	$ 50.05
Exercisable at end of the period (in dollars per share)	$ 31.19	$ 57.75
Weighted Average Remaining Contractual Term
Outstanding	7 years 9 months 18 days	7 years 9 months 18 days	7 years 6 months	6 years 7 months 6 days
Granted	9 years 6 months	6 years
Exercisable at end of the period	7 years 2 months 12 days	5 years 9 months 18 days
Aggregate Intrinsic Value
Outstanding	$ 0	$ 5,000	$ 0	$ 0
Exercisable at end of the period	$ 0	$ 0

Stock-Based Compensation - Se_4

Stock-Based Compensation - Service Based Stock Options - Others (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expenses	$ 98	$ 433	$ (82)	$ 197
Stock option awards - service based awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			909	138,378
Forfeited (in shares)			24,488	25,251
Expirations (in shares)			81,695	115,141
Stock based compensation expenses	72	$ 344	$ 272	$ 735
Unrecognized stock-based compensation expenses	$ 700		$ 700
Unrecognized stock-based compensation expense, weighted average remaining term (in years)			3 years 3 months 18 days

Licensing Agreements (Details)

Licensing Agreements (Details)	Oct. 07, 2018 agreement	Jun. 30, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of additional agreements \| agreement	3
Master Services And Ip Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, accrued reimbursement of IP expenses and sublicense royalty fees		$ 77,900
Milestone payments		$ 0

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Thousands	Jun. 30, 2022 USD ($) ft²	Dec. 31, 2021 USD ($)
Lessee, Lease, Description [Line Items]
Operating lease and finance lease liabilities \| $	$ 6,900
Operating lease and finance lease, right of use assets, net \| $	6,671	$ 7,737
Operating lease liabilities \| $	$ 4,028	7,900
Operating lease, right of use assets \| $		$ 7,700
Wixom, Michigan \| Wixom, Michigan Property One
Lessee, Lease, Description [Line Items]
Facility sqft.	51,000
Wixom, Michigan \| Wixom, Michigan Property Two
Lessee, Lease, Description [Line Items]
Facility sqft.	17,500
Grapevine, Texas
Lessee, Lease, Description [Line Items]
Facility sqft.	51,000
Greer, South Carolina
Lessee, Lease, Description [Line Items]
Facility sqft.	57,000
Hackensack, New Jersey
Lessee, Lease, Description [Line Items]
Facility sqft.	4,100
Maximum
Lessee, Lease, Description [Line Items]
Lease term	6 years

Leases - Summary of Lease Costs

Leases - Summary of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating leases
Operating lease cost	$ 431	$ 432	$ 880	$ 851
Variable lease cost	92	90	187	192
Operating lease expense	523	522	1,067	1,043
Finance leases
Amortization of right-of-use assets	141	67	282	112
Interest on lease obligations	45	20	92	33
Finance lease expense	186	87	374	145
Short-term lease rent expense	4	4	8	8
Total rent expense	713	613	1,449	1,196
Other information
Operating cash flows from operating leases	447	428	911	853
Operating cash flows from finance leases	45	21	92	34
Financing cash flows from finance leases	119	56	237	93
Right of use assets exchanged for operating lease liabilities	0	1,476	0	3,371
Right of use assets exchanged for finance lease liabilities	$ 0	$ 316	$ 0	$ 777
Weighted-average remaining lease term – operating leases	3 years 2 months 12 days	3 years 6 months	3 years 2 months 12 days	3 years 6 months
Weighted-average remaining lease term – finance leases	4 years 10 months 24 days	5 years 6 months	4 years 10 months 24 days	5 years 6 months
Weighted-average discount rate – operating leases	6.30%	6.20%	6.30%	6.20%
Weighted-average discount rate – finance leases	6.40%	5.50%	6.40%	5.50%

Leases - Finance Lease and Oper

Leases - Finance Lease and Operating Lease Maturities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Operating
Year ending December 31, 2022 (remaining)	$ 861
Year ending December 31, 2023	1,456
Year ending December 31, 2024	1,114
Year ending December 31, 2025	637
Year ending December 31, 2026	260
Remaining future payments	120
Total	4,448
Less present value discount	(420)
Operating lease liabilities	4,028	$ 7,900
Finance
Year ending December 31, 2022 (remaining)	331
Year ending December 31, 2023	669
Year ending December 31, 2024	672
Year ending December 31, 2025	676
Year ending December 31, 2026	666
Remaining future payments	310
Total	3,324
Less present value discount	(470)
Finance lease liabilities	$ 2,854

Loans and Security Agreement -

Loans and Security Agreement - Narrative (Details) - Term loan			3 Months Ended		6 Months Ended
	Sep. 24, 2021 USD ($) installment	Mar. 16, 2020 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)
Term loan
Debt Instrument [Line Items]
Aggregate principal amount	$ 7,500,000	$ 35,000,000
Calculation for number of shares of common stock able to be purchased by warrant, percentage of principal amount of relevant term loan funded funded		3.50%
Warrant exercise price calculation, period immediately preceding execution of loan agreement, number of trading days		5 days
Interest rate, base percentage		4.75%
Interest rate, additional percentage added to base percentage		4%
Initial interest rate percentage		8.75%
Effective interest rate		10.90%
Option to add interest rate amount to outstanding principal balance in lieu of paying such amount in cash, percentage		1%
Interest expense			$ 400,000	$ 600,000	$ 1,200,000	$ 800,000
Number of monthly installments \| installment	10
Prepayment premium percentage	5%
Minimum liquidity floor	$ 5,000,000
Minimum principal amount pursuant to liquidity covenant	$ 15,000,000
Outstanding balance, net of unamortized issuance costs and unaccreted discount			15,500,000		15,500,000
Unamortized issuance costs and unaccreted discount			$ 1,000,000		$ 1,000,000
Term loan \| Minimum
Debt Instrument [Line Items]
Period for which company is entitled to make interest-only payments		30 months
Term loan \| Maximum
Debt Instrument [Line Items]
Period for which company is entitled to make interest-only payments		36 months
Term loan, first tranche
Debt Instrument [Line Items]
Aggregate principal amount		$ 22,500,000
Net draw down proceeds		21,200,000
Closing costs		$ 1,300,000
Exercise price of warrant (in dollars per share) \| $ / shares		$ 18.15
Number of shares of common stock for which warrant is exercisable (in shares) \| shares		43,388
Additional debt discount recognized		$ 500,000
Term loan, second and third tranches
Debt Instrument [Line Items]
Warrant exercise price calculation, period immediately preceding relevant funding, number of trading days		5 days
Term loan, second and third tranches \| Maximum
Debt Instrument [Line Items]
Exercise price of warrant (in dollars per share) \| $ / shares		$ 18.15
Term loan, second tranche
Debt Instrument [Line Items]
Aggregate principal amount		$ 5,000,000
Term loan, third tranche
Debt Instrument [Line Items]
Aggregate principal amount		$ 7,500,000

Loans and Security Agreement _2

Loans and Security Agreement - Schedule of Principal Payments on Term Loan (Details) - Term loan - Term loan $ in Thousands	Jun. 30, 2022 USD ($)
Debt Instrument [Line Items]
2022	$ 2,500
2023	6,000
2024	6,000
2025	2,000
Principal Payments	$ 16,500

Insurance Financing Note Paya_2

Insurance Financing Note Payable (Details) - 5.40% Note Payable - Notes Payable to Banks - USD ($) $ in Millions	Jun. 02, 2022	Jun. 30, 2022
Short-term Debt [Line Items]
Short-term note payable	$ 1.5
Interest rate, base percentage	5.40%
Amortization period (in months)	9 months
Outstanding amount		$ 1.5

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Aug. 10, 2022	Jul. 14, 2022	May 30, 2022
PIPE Purchase Agreement Pre-Funded Warrant
Subsequent Event [Line Items]
Exercise price of warrant (in dollars per share)			$ 0.0001
Subsequent event
Subsequent Event [Line Items]
Gross proceeds	$ 31.50	$ 95.29
Subsequent event \| PIPE Purchase Agreement Pre-Funded Warrant
Subsequent Event [Line Items]
Warrants excercised	315,000	952,897
Exercise price of warrant (in dollars per share)	$ 0.0001	$ 0.0001